Should the PANSS be rescaled?

Schizophrenia Bulletin

Volumn 36, Issue 3, 2010, Pages 455-460

  Obermeier, Michael ^a   Mayr, Andreas ^a   Schennach Wolff, Rebecca ^a   Seemüller, Florian ^a   Möller, Hans Jürgen ^a   Riedel, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Minimum subtraction; Percent change; Scale level; Simulation study

Indexed keywords

ADULT; ARTICLE; CALCULATION; DECISION MAKING; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RATING SCALE; STATISTICAL ANALYSIS; SYMPTOM;

ADULT; ANTIPSYCHOTIC AGENTS; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 77953196227     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbp124     Document Type: Article

References (20)

1. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr.Bull. 1987;13:261-276.
2. Kay SR, Opler LA, Fiszbein A. The Positive and Negative Syndrome Scale (PANSS) Manual. Toronto, ON: Multi-Health Systems Inc.; 2000.
3. Tornqvist L, Vartia P, Vartia YO. How should relative changes be measured? Am Stat. 1985;39:43-46.
4. Berry DA, Ayers GD. Symmetrized percent change for treatment comparisons. Am Stat. 2006;60:27-31.
5. Fleischhacker WW, Kemmler G. The clinical relevance of percentage improvements on the PANSS score. Neuropsycho-pharmacology. 2007;32:2435-2436.
6. Leucht S, Davis JM, Engel RR, Kane JM, Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharma-cology. 2007;32:1903-1910.
7. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835.
8. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry. 1995;166:712-726.
9. Labelle A, Boulay LJ, Lapierre YD. Retention rates in placebo-and nonplacebo-controlled clinical trials of schizophrenia. Can J Psychiatry. 1999;44:887-892.
10. Labelle A, Light M, Dunbar F. Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response. Can J Psychiatry. 2001;46:534-541.
11. Lee BH, Kim YK. Increased plasma brain-derived neuro-tropic factor, not nerve growth factor-Beta, in schizophrenia patients with better response to risperidone treatment. Neuro-psychobiology. 2009;59:51-58.
12. Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res. 2009;110:80-89.
13. FDA: U.S. Food and Drug Administzration. Drug approval package for zyprexa intramuscular (olanzapine) injection, Application No. 021253, Approval Date 3/29/2004. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2004/21253- Zyprexa.TOC.cfm. Accessed July 13, 2005.
14. Spina E, Avenoso A, Facciola G, et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psycho-pharmacology (Berl). 2001;153:238-243.
15. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med. 2006;354:472-482.
16. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59:441-448.
17. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-771.
18. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl. 2009;438:7-14.
19. R Development Core Team Organization: R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing. Vienna, Austria. http://www.R-project. org. 2009.
20. Fahrmeir L, Künstler R, Pigeot I, Tutz G. Statistik: Der Weg zur Datenanalyse, 4. Berlin, Germany: Springer; 2003.